This table presents recent patent oppositions filed by Glenmark Pharmaceuticals Europe Ltd against its competitors. It outlines key details of each case, including the patent title, filing date and the applicant. This information provides insights into the competitive landscape and highlights active disputes over patent grant within the industry.

Patent NumberTitleApplicantOpposition Date
EP3578175Rapid Dissolution Formulation Of A Calcium Receptor-Active CompoundAMGENAug 30, 2023
EP2653873Compositions And Uses For Treating Multiple SclerosisBIOGEN IDEC MA INC.Apr 19, 2023
EP2959894S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS AGOct 12, 2022
EP2817000Oral Pharmaceutical Compositions Of Dabigatran EtexilateESTEVE PHARMACEUTICALS, S.A.Apr 14, 2022
EP2478907Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGY, INC.Jan 14, 2022
EP2493466Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMA S.A.Mar 10, 2021
EP3395338Rapid Dissolution Formulation Of Cinacalcet HclAMGENJan 27, 2020
EP3260117Rapid Dissolution Formulation Of A Calcium Receptor-Active CompoundAMGENJan 16, 2020
EP3395339Rapid Dissolution Formulation Of A Cinacalcet HclAMGENJan 16, 2020
EP3395340Rapid Dissolution Formulation Of Cinacalcet HclAMGENJan 16, 2020